Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio

Company Expands on Issued Patent to Create Novel Approach to Selectively Killing Tumor Cells SAN DIEGO, Jan. 20, 2023 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies,…

Click here to view original post